tamoxifen

P2, N=176, Recruiting, Memorial Sloan Kettering Cancer Center

After the discontinuation of tamoxifen treatment, the lesion gradually decreased in size. Although tamoxifen-induced peliosis hepatis is rare, it should be considered in the differential diagnosis of hepatic lesions.

P3, N=4800, Recruiting, Shandong Suncadia Medicine Co., Ltd. | Not yet recruiting --> Recruiting

P2, N=33, Active, not recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Mar 2026 --> Sep 2026

This study provides new insights into the mechanistic impact of FULV on ER activity, highlighting its ability to modulate H3K27ac dynamics even in the absence of transcriptional changes. These findings underscore the complexity of ER signaling and further suggest that FULV's therapeutic effects may extend beyond simple antagonism of ER activity.

P1, N=50, Recruiting, Finn, Olivera, PhD | Trial completion date: Aug 2028 --> Mar 2029 | Trial primary completion date: Jan 2026 --> Aug 2026

These findings underscore the critical roles of CFL2 and tamoxifen in orchestrating actin organization and plasticity, chemoresistance, and indicate potential strategies for reversing therapeutic resistance.

Herein, we developed and evaluated an ERα-targeted fluorescent probe (IRDye800-4OHT) by conjugating ERα targeting ligand 4-hydroxytamoxifen with near-infrared fluorescence dye IRDye800CW for ERα+ BC detection via imaging ERα...Moreover, in vivo NIR-II imaging clearly revealed that IRDye800-4OHT enabled real-time imaging of ERα, specifically illuminated tumor tissue, and successfully guided breast tumor resection. Therefore, we postulate that IRDye800-4OHT can serve as a valuable tool for the precise diagnosis and surgical excision of ERα-positive tumors.

P=N/A, N=1545, Completed, Ente Ospedaliero Ospedali Galliera | Not yet recruiting --> Completed | N=500 --> 1545 | Trial completion date: Feb 2035 --> Mar 2026 | Initiation date: Jun 2026 --> Jul 1996 | Trial primary completion date: Oct 2026 --> Mar 2026

Palbociclib 100 mg was associated with a reduced incidence of ≥grade 3 neutropenia. While PFS was numerically lower at 100 mg, the difference was not statistically significant and was limited by sample size and complicated by varying degrees of pre-treatment. Analysis of skin and tumor pRb or Ki-67 demonstrated robust molecular response at both doses. PIK3CA and TP53 mutations and higher baseline Ki-67 were associated with inferior clinical outcome.

Pristimerin effectively ameliorates gastric mucosal pathological damage and oxyntic atrophy in high-dose tamoxifen-induced SPEM mice, and improves SPEM progression by modulating Cdkn1c (p57)-mediated glycolytic reprogramming.